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Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease that causes
degeneration of the lower and upper motor neurons and is the most prevalent motor
neuron disease. This disease is characterized by muscle weakness, stiffness, and
hyperreflexia. Patients survive for a short period from the onset of the disease. Most
cases are sporadic, with only 10% of the cases being genetic. Many genes are
now known to be involved in familial ALS cases, including some of the sporadic
cases. It has also been observed that, in addition to genetic factors, there are
numerous molecular mechanisms involved in these pathologies, such as excitotoxicity,
mitochondrial disorders, alterations in axonal transport, oxidative stress, accumulation of
misfolded proteins, and neuroinflammation. This pathology affects the motor neurons,
the spinal cord, the cerebellum, and the brain, but recently, it has been shown that
it also affects the visual system. This impact occurs not only at the level of the
oculomotor system but also at the retinal level, which is why the retina is being proposed
as a possible biomarker of this pathology. The current review discusses the main
aspects mentioned above related to ALS, such as the main genes involved, the most
important molecular mechanisms that affect this pathology, its ocular involvement, and
the possible usefulness of the retina as a biomarker.
Keywords: ALS, motor neuron, neurodegenerative diseases, retina, optic nerve, eye, neuroinflammation,
biomarker
INTRODUCTION: OVERVIEW OF AMYOTROPHIC LATERAL
SCLEROSIS DISEASE
Motor neuron diseases (MNDs) have a high morbidity and mortality and cause a gradual
deterioration of voluntary muscle function due to progressive neuronal damage (Rowland and
Shneider, 2001; Turner et al., 2009; Yedavalli et al., 2018; Pinto et al., 2019). MND has a global
incidence of one to three cases per 100,000, while its prevalence ranges from one to nine cases
per 100,000. Within the group of these diseases, amyotrophic lateral sclerosis (ALS) is the most
common, accounting for 80–90% of all MND cases (Román, 1996) and having an incidence
per 100,000 people of 0.3–2.5 cases per year (Rowland and Shneider, 2001; Sathasivam, 2010;
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Kiernan et al., 2011; Pratt et al., 2012). Of all ALS cases, 10%
are familial (FALS) (Byrne et al., 2011) ranging from 2% to
15% depending on the population (Conwit, 2006). Overall, both
the incidence (Haberlandt, 1959) and the prevalence (Williams
et al., 1988) of this pathology can be variable depending on the
region and ethnicity.
In ALS, a combination of the symptoms of both upper motor
neurons (UMNs) and lower motor neurons (LMNs) occurs
(Rowland and Shneider, 2001; Kiernan et al., 2011; Yedavalli
et al., 2018). This condition involves muscle weakness and
stiffness, overactive reflexes, and sometimes changes in emotions
(Carra et al., 2012; Zarei et al., 2015; Yedavalli et al., 2018). ALS
involves the swallowing, speech, and respiratory muscles (Carra
et al., 2012; Zarei et al., 2015; Yedavalli et al., 2018). The disease
usually begins in the extremities (spinal onset), although 25%
of patients have a bulbar onset, which has a worse prognosis
(Kiernan et al., 2011). ALS is a disease that is asymmetrical with
respect to the onset and spread of UMN and LMN dysfunction
and constitutes a heterogeneous disease, because not all forms
behave in the same way, which makes its classification complex
(Zhang et al., 2014).
Although ALS has only been considered a motor disease,
neuroimaging tests have recently shown the involvement of non-
motor areas such as cerebral global atrophy, decrease in gray
matter density, and regional white matter alterations (Ellis et al.,
2001; Abrahams et al., 2005; Kassubek et al., 2005; Ringholz et al.,
2005; Mezzapesa et al., 2007; Zhang et al., 2014). The alteration of
these areas leads to cognitive and behavioral changes (Abrahams
et al., 2005; Mezzapesa et al., 2007). Cognitive impairment,
mainly featuring executive dysfunction and mild memory loss
during the course of the disease, has been found in 50% of ALS
patients (Ringholz et al., 2005; Meier et al., 2010).
Mechanisms and Risk Factors Involved
in the Pathogenesis of Motor Neuron
Diseases
There are different risk factors involved in ALS (Yu et al., 2014;
Zarei et al., 2015), which include smoking (Weisskopf et al.,
2009; Wang et al., 2014), agricultural chemicals (Ward et al.,
2014; Seals et al., 2017), heavy metals (Simons, 1986; Mcguire
et al., 1997; Savolainen et al., 1998; Kamel et al., 2002), and low-
frequency electromagnetic waves (Zhou et al., 2012). In addition,
athletes (Chiò et al., 2004; Turner et al., 2012; Zarei et al., 2015)
and hypermetabolic phenotype (Desport et al., 2001; Bouteloup
et al., 2009; Vaisman et al., 2009; Dupuis et al., 2011; Ferri and
Coccurello, 2017; Steyn et al., 2018; Pape and Grose, 2020) have
a higher risk for ALS. A low body mass index can induce disease
progression and reduced survival time (Jawaid et al., 2010; Park
et al., 2015). Other factors that may affect ALS patients are
hyperlipidemia (Palamiuc et al., 2015) and glutamate-rich and
fat-rich diets (Iwasaki et al., 2005; Veldink et al., 2007; Morozova
et al., 2008; Fitzgerald et al., 2014). However, progesterone and
estrogen provide protection against ALS (Gargiulo Monachelli
et al., 2011; De Jong et al., 2013; Pape and Grose, 2020).
Several molecular mechanisms can cause neurodegeneration
in ALS (De Vos et al., 2000; Magrané and Manfredi, 2009;
Shi et al., 2010; Forsberg et al., 2011; Zhu and Sheng, 2011;
Donnelly et al., 2013; Jaiswal, 2014; Mitsumoto et al., 2014; Wang
et al., 2014), and others can be considered secondary in the
development of ALS (Vucic and Kiernan, 2007).
Glutamate Excitotoxicity
Glutamate has a neurotoxic effect when it accumulates at the
synapses (Gazulla and Cavero-Nagore, 2006). In patients with
ALS (both spinal cord and motor cortex involvement), and in
the superoxide dismutase 1 (SOD1) transgenic mouse model, a
decrease in glutamate receptors (GluRs) was found in astrocytes.
This decrease induces extracellular glutamate accumulation,
which causes overstimulation of GluRs and neuronal death via
excitotoxicity (Lin et al., 1998; Trotti et al., 1999; Barbeito et al.,
2004; Pratt et al., 2012). In ALS patients, a decrease in glutamate
transporters is mainly due to an alteration in messenger RNA (Lin
et al., 1998; Honig et al., 2000).
Structural and Functional Abnormalities of the
Mitochondria
Mitochondrial function disturbances, such as fragmentation and
aggregation, are frequently found in ALS patients (Vielhaber
et al., 2000; Chung and Suh, 2002; Krasnianski et al., 2005;
Echaniz-Laguna et al., 2006; Crugnola et al., 2010; Cozzolino and
Carrì, 2012). Increased crests, swelling, and fragmentation have
been observed in the mitochondria of the spinal motor neurons
and proximal axons of skeletal muscle in ALS-related tissues
(Chung and Suh, 2002; Echaniz-Laguna et al., 2002; Boillée
et al., 2006a). The increase in the misfolded SOD1 enzyme in
the mitochondria of the spinal cord of mice is considered to
be the main cause of mitochondrial dysfunction. In addition,
aggregates of the enzyme SOD1 may also interact with the
apoptosis regulator protein Bcl-2, inducing an apoptotic cascade
and contributing to the deterioration of neurons and neuro-
muscular degeneration (Boillée et al., 2006a).
Impaired Axonal Structure and Transport Defects
Axonal transport (retrograde and anterograde) is impaired in
ALS patients and in mutant SOD1 mice, as evidenced by
the accumulation of altered structures, such as mitochondria,
neurofilaments, and autophagosomes, in the spinal motor neuron
axons (Ikenaka et al., 2012; Zarei et al., 2015). Mutations in
the dynein genes have been seen in models of ALS mice.
Dyneins are responsible for the transport of mitochondria
and autophagosomes, causing both to accumulate in the axon
(Ikenaka et al., 2012). Autophagosomes are necessary for the
elimination of altered mitochondria and dilated endoplasmic
reticules, which accumulate in the axons of motor neurons
and cause them to malfunction (Zarei et al., 2015). All of the
above suggest that an alteration in axonal transport could be
fundamental for the development of ALS.
Free Radical-Mediated Oxidative Stress
Increased free radical and oxidative damage has been found in
biopsies from ALS patients, as well as in cerebrospinal fluid,
serum, and urine samples (Simpson et al., 2004; Shin Hee and
Lee Keun, 2013). This oxidative damage also affects RNA, which
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has been shown in both human central nervous system (CNS)
biopsies and in mouse ALS models of SOD1 (Chang et al.,
2008). The enzyme SOD1 is an important anti-oxidant. The
alterations in the redox reactions are one of the first theories
of how mutations in SOD1 can cause cytotoxicity (Carrì et al.,
2015). In addition, it has been observed in the motor cortex, using
positron emission tomography (PET), that increased oxidative
stress is related to the severity of the disease in ALS patients
(Tsujikawa et al., 2015).
Protein Aggregates
It has been shown that in ALS, abnormal protein accumulations
are produced that aid in the pathogenesis of the disease (Blokhuis
et al., 2013). The ubiquitin–proteasome (UP) system, which
repairs and removes proteins, plays an important role in ALS,
with ubiquitin-reactive inclusions being characteristic of this
pathology (Han-Xiang et al., 2011; Pratt et al., 2012). Among
these, the inclusions of proteins TDP-43 and p62 are indicative
of this pathology (Al-Sarraj et al., 2011; Williams et al., 2016).
Some ALS patients present numerous inclusions positive for p62
but negative for TDP-43 in the hippocampus and cerebellum
(Al-Sarraj et al., 2011). These p62-positive and TDP-43-negative
inclusions have also been observed in other CNS areas including
the retina (Brettchneider et al., 2013; Fawzi et al., 2014).
Neuroinflammation
Neuroinflammation occurs in many neurodegenerative diseases,
such as Parkinson’s, Alzheimer’s, and ALS, resulting in the
activation of astroglial and microglial cells (Ramírez et al.,
2017). Specifically, in ALS, it has been observed that reactive
glia (microglia and astrocytes) can influence the damage and
subsequent death of motor neurons (Vargas and Johnson, 2010;
Philips and Robberecht, 2011; Liao et al., 2012). In the ALS,
the presence of mutant proteins (SOD1 and TDP-43), oxidative
stress, mitochondrial damage, etc., produces continuous damage,
which can trigger a chronic activation of glial cells and, therefore,
a sustained inflammatory process that could exacerbate neuronal
damage (Philips and Robberecht, 2011). It has been observed that
the mutant SOD1 protein can have a toxic function on motor
neurons only when the activated microglia is present through a
mechanism involving a toll receptor (CD14-TLR) that causes an
increase in free radicals (Zhao et al., 2010). Astrocyte activation
(Vargas and Johnson, 2010), microglial activation (Alexianu et al.,
2001), and lymphocyte appearance (Engelhardt et al., 1993)
have been found in animal models of ALS (mutants of SOD1)
(Alexianu et al., 2001; Boillée et al., 2006b) and in ALS patients
(Kushner et al., 1991; Kawamata et al., 1992; Nagy et al., 1994;
Schiffer et al., 1996; Turner et al., 2004). In both cases, the
mutant SOD1 causes the microglia to increase the expression of
pro-inflammatory cytokines, such as IL-1β and TNF-α (Weydt
et al., 2004), and inflammatory mediators, such as cyclooxygenase
2 (COX-2) (Almer et al., 2001) and nitric oxide (NO). The
NO released by the microglia could induce apoptosis in motor
neurons through the activation of Fas via (Raoul et al., 2002).
Mutant protein TDP-43 can produce microglial activation
through the surface receptor CD14, which stimulates the NF-
κB and AP-1 pathways and the inflammasome. This can cause a
neurotoxic cascade leading to motor neuron death (Zhao et al.,
2015). In the ALS SOD1 model, the microglia isolated at the
onset of the disease has an M2 or anti-inflammatory phenotype;
however, the microglia isolated at the end of the disease has
a neurotoxic M1 phenotype. This demonstrates a dual role of
microglial cells during the disease process in this ALS model
(Liao et al., 2012).
Astrogliosis has been observed in ALS models with mutations
in C9orf72, FUS, SOD1, and TARDBP genes (Wong et al.,
1995; Liu et al., 2016; Sharma et al., 2016). In the last model,
the death of the motor neurons could be due, in part, to a
loss of the function of the TDP-43 protein in the astrocytes
(Yang et al., 2014). In ALS SOD1 models, astrocytes can release
ATP, causing the activation of microglial cells via purinergic
receptors (P2X7) (Gandelman et al., 2010). They can also
release transforming growth factor-β1 (TGF-β1), which can
induce microglial inactivation, thereby eliminating the possible
beneficial effects of the microglia and, thus, accelerating the
progression of the pathology (Endo et al., 2015). Moreover, the
microglia in ALS can affect astrocytes by favoring the appearance
of a neurotoxic subtype (Liddelow et al., 2017).
Considering all of the above, both the microglia and reactive
astrocytes can affect neural function in ALS by playing an
important role in the progression of the disease.
Genetics
Although most cases (90–95%) of ALS are sporadic (SALS)
and not inherited, 10% of cases are of genetic origin (Byrne
et al., 2011). Specific genetic locus mutations have been found
to constitute the cases of FALS (Deivasigamani et al., 2014). The
pattern of inheritance depends on the genes involved. Most cases
are inherited in an autosomal dominant pattern (He et al., 2015).
Men show more intense symptoms of the disease than women.
There are many genes involved in the development of this disease.
In FALS, mutations in the C9orf72 gene represent 30–40% of
cases, those in the SOD1 gene make up 15–20%, those in the FUS
and TARDBP genes each represent approximately 5% of cases,
and the remaining genes that have been associated with FALS
each represent a small proportion of cases (Pratt et al., 2012;
Blokhuis et al., 2013). We next describe some of these genes.
C9orf72 Gene
This gene is located at the locus 9p21 of chromosome 9. It
has been proposed that the C9orf72 mutation can decrease
the C9orf72 protein, thus causing less endocytosis, which is
necessary for autophagy (Mathis et al., 2019). Moreover, the
massive accumulation of the expanded hexanucleotide GGGGCC
could be neurotoxic and sequester proteins that bind to RNA,
thereby causing the disruption of the machinery that processes
RNA (Mathis et al., 2019). This mutation could also lead to
increased vulnerability to excitotoxicity due to increased calcium
permeability mediated by AMPA type receptors (Selvaraj et al.,
2018). The form of inheritance is autosomal dominant, although
some carriers do not develop the disease, so it has an incomplete
penetrance (Renton et al., 2011). This variant represents the most
frequent cause of SALS (7%) and FALS (30–40%) (Majounie et al.,
2012). The manifestations at the onset of the disease are typical of
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ALS and have a bulbar onset. This variant is often associated with
an earlier age of onset, a faster clinical course, and shorter survival
(Schymick and Traynor, 2010).
FUS Gene
The FUS gene, located on the short arm of chromosome 16
(16p11.2), encodes a protein called sarcoma fusion protein (FUS)
(Hübers et al., 2015; Scekic-Zahirovic et al., 2017). In ALS,
mutations in the FUS gene have been observed, most of which
can produce changes in amino acids in the region of the protein
related to DNA binding and mRNA processing. These mutations
may interfere with the importation of FUS into the cell nucleus,
which will cause an accumulation of FUS in the cytoplasm. This
has been observed particularly in the nerve cells that control
muscle movement (Scekic-Zahirovic et al., 2017). This mutation
occurs in 3–5% of FALS and in 1% of SALS cases (Deng et al.,
2010; Mackenzie et al., 2010). In addition, patients with FUS
mutations tend to develop the disease earlier and have a shorter
life expectancy than those observed with mutations in other
genes. Patients with ALS and FUS mutations may also develop
frontotemporal dementia (FTD) (Kwiatkowski et al., 2009; Vance
et al., 2009).
OPTN Gene
The optineurin gene (OPTN) is located on chromosome 10 and
encodes a protein called optineurin, which is a multifunctional
ubiquitin-binding phosphoprotein found in the cytoplasm.
Changes of this protein can cause alterations in intracellular
traffic and lead to inclusions in ALS. In addition, this protein is
also involved in the signaling of the tumor necrosis factor α/NF-
κB pathway (Zhu et al., 2007) and the mGluR (Ying et al., 2010).
In 2010, Maruyama et al. (2010) and Schymick and Traynor
(2010) found mutations in the OPTN gene in ALS patients. These
mutations are present in 1.2% of patients with FALS (Del Bo
et al., 2011). ALS patients with OPTN mutations presented typical
spinal-onset disease (Weishaupt et al., 2013). Mutations in this
gene were previously shown to be involved in primary open-angle
glaucoma (Maruyama et al., 2010). This gene has also been linked
to normotensional glaucoma in ALS patients (Weishaupt et al.,
2013). In cells from patients with SALS and FALS, optineurin
can be placed in inclusion bodies with TDP-43 (Maruyama et al.,
2010), FUS (Ito et al., 2011), and SOD1 (Maruyama et al., 2010).
Both retinal ganglion cells (RGCs) and motor neurons share
common susceptibility factors (Weishaupt et al., 2013).
SOD1 Gene
The SOD1 gene is located on the long arm of chromosome
21 (21q22.11). This gene encodes a cytosolic enzyme called
copper zinc (Cu/Zn) SOD1 (Gatchel and Zoghbi, 2005; Valentine
et al., 2005) that plays a very important role in the elimination
of superoxide radicals, thereby protecting against free radicals
(Azadmanesh and Borgstahl, 2018). Around 2.5–23% of patients
with FALS and 0.44–7% of those with SALS have mutations in
SOD1 (Andersen, 2006; Van Es et al., 2010). Most of the inherited
forms of SOD1 gene mutations are dominant (Hayward et al.,
1998; Marucci et al., 2007). Mutations in the SOD1 enzyme can
induce configurational changes in the SOD1 protein leading to
motor neuron toxicity (Mathis et al., 2019). ALS patients who
present mutations in SOD1 show an earlier time of onset and
a longer duration of disease. In addition, they usually do not
present cognitive disorders, and their motor symptoms usually
begin in the lower extremities (Mathis et al., 2019).
TARDBP Gene
The Tar DNA binding protein (TARDBP) gene is located on the
short arm of chromosome 1 (1p36.22) and encodes the TDP-
43 protein. More than 40 mutations have been identified in
the TARDBP gene and result in 6.5% of FALS cases. The form
of inheritance is dominant (Kühnlein et al., 2008; Van Deerlin
et al., 2008) and represents 0–5% of SALS cases (Kühnlein et al.,
2008; Rutherford et al., 2008; Sreedharan et al., 2008). Most of
the mutations cause changes in the amino acids in the TDP-
43 protein and affect the region of the protein involved in
the processing of RNA (Neumann et al., 2006; Da Cruz and
Cleveland, 2011). Cytoplasmic inclusions of ubiquitin-reactive
hyperphosphorylated TDP-43 proteins have been found in tissues
of patients with FTD (Arai et al., 2006; Neumann et al., 2006).
These inclusions have also been seen in the glial tissue and
neurons of patients with SALS (Maekawa et al., 2009). These
inclusions can often be placed with p62 and ubiquitin but are
not found in FALS with FUS mutation (Vance et al., 2009) or
SOD1 mutation (Mackenzie et al., 2007). Some patients with
FALS and TARDBP mutation may also develop FTD (Arai et al.,
2006; Neumann et al., 2006).
MATERIALS AND METHODS
A literature search was performed up to May 2020 using
the “MESH” terms in PubMed with the following keywords
and word combinations: “Amyotrophic Lateral Sclerosis,”
AND “Environmental Exposure,” “Nerve Degeneration,”
“mitochondria,” “oxidative stress,” “Protein Aggregates,”
“Microglia,” “Genetics,” “Oculomotor Muscles,” “Visual
Pathways,” “Evoked Potentials, Visual,” “Contrast Sensitivity,”
“Visual Fields,” “Visual Field Tests,” “Visual Acuity,” “Retina,”
OR “Optical Coherence Tomography.” After filtering by author
criteria (articles published in the last 10 years), English or Spanish
language, and the condition that all address the relationship
between ALS and visual pathway as the main subject, 196 articles
were considered, and 304 articles did not satisfy the selection
criteria (Figure 1).
Inclusion criteria: Articles were selected according to the
following criteria: (i) articles focused on general features of
ALS pathology, (ii) research that related the ALS with visual
system alterations, (iii) retinal research developed in both ALS
patients and animal experimental models of ALS, and (iv)
articles based on human clinical trials with optical coherence
tomography (OCT) analysis.
Exclusion criteria: Articles were excluded with the following
characteristics: (i) research not carried out in mammalian
experimental models of ALS and (ii) articles that did not have the
sufficient outcomes associated with the objective of this review or
did not meet the selection criteria of the authors.
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FIGURE 1 | Flow chart materials and methods.
AMYOTROPHIC LATERAL SCLEROSIS
AND THE EYE
As discussed above, ALS affects not only motor neurons, the
spinal cord, the cerebellum, and large areas of the brain but also
the visual system, including the oculomotor and visual pathways.
However, patients usually do not have visual complaints. For
this reason, studies focusing on the visual pathway are not
common. Most previous studies were related to the oculomotor
function and the study of visual evoked potentials (VEPs) that
analyze the visual pathway. However, some studies of ALS
have subsequently emerged that are more related to visual
function, using tests such as visual acuity, contrast sensitivity,
and visual field (VF). In addition, the retina has now been
described as a “window to the brain,” and the changes that
the brain suffers in neurodegenerative diseases can also appear
in the retinal tissue (MacCormick et al., 2015). Changes in
retinal tissue can be detected using OCT, which is a diagnostic
technique widely used in ophthalmology and has recently been
used for the analysis of retinal and optic nerve changes in
neurodegenerative diseases such as ALS disease. This technique
can help in the diagnosis and follow-up of these pathologies
(Salobrar-García et al., 2015a,b, 2016).
The following is a description of the main alterations found
in this visual system using the aforementioned techniques and
tests (Figure 2).
Oculomotor Function Alterations
Amyotrophic lateral sclerosis is a condition that affects motor
neurons and large areas of the brain, so ocular movements may
be affected. Thus, numerous studies on oculomotor function
have appeared since the 1980s and continue to appear today
(Table 1 and Figure 2). Although oculomotor function is
generally retained in ALS patients, they may manifest various
oculomotor dysfunctions both at a relative early stage and in
advanced stages of the disease. These include (i) a worsening
of saccadic and pursuit eye movements (Leveille et al., 1982;
Cohen and Caroscio, 1983; Saito and Yamamoto, 1989; Gizzi
et al., 1992; Marti-Fàbregas and Roig, 1993; Ohki et al., 1994; Abel
et al., 1995; Shaunak et al., 1995; Okuda et al., 2009; Donaghy
et al., 2010; Moss et al., 2012; Kang et al., 2018); (ii) a lack of
suppression of the vestibulo-ocular reflex (Ohki et al., 1994); (iii)
a significant increase in error rates (distraction) and latency in
anti-saccadic movements (Shaunak et al., 1995; Donaghy et al.,
2010) that may evoke saccadic paradigms, head shaking (Kang
et al., 2018), and positional nystagmus of central origin (Saito
and Yamamoto, 1989; Marti-Fàbregas and Roig, 1993; Ohki et al.,
1994; Kang et al., 2018); (iv) gaze fixation instability (Saito and
Yamamoto, 1989; Palmowski et al., 1995; Shaunak et al., 1995;
Donaghy et al., 2009; Moss et al., 2012; Kang et al., 2018); (v)
eyelid opening apraxia (Averbuch-Heller et al., 1998; Moss et al.,
2012); and (vi) square wave jerks (Gizzi et al., 1992; Shaunak
et al., 1995; Kang et al., 2018), which may reflect the incidence
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FIGURE 2 | Visual and retinal features in amyotrophic lateral sclerosis (ALS). The retinal scheme represents the main histological findings found in retinas with ALS.
TABLE 1 | Previous studies of extraocular movements in ALS patients.
Study and year of
publication





ALSFRS score Alterations in ocular movements in ALS
Leveille et al., 1982 – 10/– – – ↓Saccadic pursuit, unidirectional saccadic pursuit, ↓saccadic velocities
Saito and
Yamamoto, 1989
Observational 23/100 – – Slight limitations of upward only, upward and downward and upward
and horizontal gaze, incomplete convergence, horizontal gaze




Cross-sectional 13/16 29.09 – ↑Saccadic latencies and ↓smooth pursuit gain. Positive relationship
between smooth pursuit saccadic intrusions and the bulbar clinical
score and the rate of progression and a ↓optokinetic nystagmus
maximal velocity in patients with pseudobulbar syndrome
Shaunak et al.,
1995
Cross-sectional 17/11 24.5 (6–60) – ↑Error rates (distractibility) and latency in the anti-saccade and




Cross-sectional 30 spinal and 14
bulbar/45
52 35 (18–47) ↓Reflexive saccades in bulbar-onset vs. to spinal-onset patients and
controls. ↑Anti-saccade latency and ↑anti-saccade type 1 errors.
↓“Proportion of time spent in smooth pursuit” and ↓smooth pursuit
“velocity gain”
Moss et al., 2012 Cross-sectional 63/37 43.2 ± 37.25
(7.2–204)
16 (6–46) Gaze impersistence, voluntary upgaze restriction, eyelid opening
apraxia, saccadic horizontal pursuits
Ohki et al., 1994 Observational 9/– 13 (3–49) Early stages ↓Velocity of saccades. Abnormalities of smooth pursuit, optokinetic





61/39 38.6 (31) 33.5 (6.5) ↓Executive and visual search tasks; normal basic saccadic function.
↓Anti-saccade performance, ↑error rate and latency




Spinal 55.1 ± 9.5,
bulbar 62.2 ± 11.1
– Square wave jerks, saccadic dysmetria, abnormal cogwheeling smooth
pursuits, head shaking, and positional nystagmus of central origin. ↑
Abnormal smooth pursuits and saccadic dysmetria
ALS, amyotrophic lateral sclerosis; ALSFRS, Amyotrophic Lateral Sclerosis Functional Rating Scale.
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of secondary abnormalities, such as parkinsonism (Gizzi et al.,
1992), and facilitate prefrontal dysfunction in these patients
(Shaunak et al., 1995). In bulbar onset compared with spinal
onset, saccadic dysmetria and abnormal cogwheeling smooth
pursuits are increased, which suggests neurodegeneration in ALS
involving more than motor neurons (dysfunction of vestibule
cerebellar connections), especially in bulbar-onset disease (Kang
et al., 2018). In a longitudinal study (Proudfoot et al., 2016),
ALS patients, even those with normal saccadic function, were
shown to have problems with executive and visual search tasks.
These impairments were often more severe than expected in ALS
patients. However, no significant progression was observed in the
longitudinal study, nor were changes found in the connectivity
of the R-FMRI network (Proudfoot et al., 2016). In the
postmortem histopathological examination of ALS patients, cell
loss was found in the substantia nigra and the rostral interstitial
nucleus of the medial longitudinal fasciculus, suggesting that
the early involvement of vertical saccades might correspond
to a different clinical–pathological type (Averbuch-Heller et al.,
1998). Therefore, as suggested by Sharma et al. (2011), changes
in the oculomotor function of ALS patients could be promising
biomarkers for the mechanical diagnosis, prognosis, and follow-
up of ALS.
The extraocular muscles (EOMs) and their motor neurons are
retained in ALS. However, from the onset of this disease, the
muscles of the limbs show axon retraction at the neuromuscular
junctions. Wnt is a preserved family of secreted signaling
molecules that are primarily involved in the formation of
neuromuscular junctions. This signaling pathway was analyzed
both in ALS patients and in a SOD1G93A mouse model for its
possible implications in the preservation of normal morphology
and the function in EOMs in this disease (McLoon et al., 2014).
The authors found differential patterns of expression for Wnt1
and Wnt3a isoforms in the EOMs for limb muscles, especially
at the neuromuscular junction level. This suggests that in ALS
patients, this signaling pathway is preserved in the EOMs and
dysregulated in the muscles of the limbs that subsequently
develop a pathology (McLoon et al., 2014).
Visual Pathway Alterations
The alteration of the visual pathway can be analyzed using VEPs,
contrast sensitivity, and VF. Next, we describe the different
alterations found in the visual pathway of each.
Visual Evoked Potentials
Few studies have analyzed the VEPs in ALS patients (Table 2 and
Figure 2). It was not until 1986 that alterations in VEPs were
found in patients with ALS, with abnormal relative difference in
latencies between each eye. In this study of 32 patients analyzed,
only four had VEP abnormalities (increased latency time);
however, these alterations were mild (Matheson et al., 1986). In
other studies, while wave latency and amplitudes were within
normal limits in all ALS patients (Ghezzi et al., 1989; Palma et al.,
1993), somatosensory evoked potentials were abnormally delayed
(N9–N13 and N13–N19 latencies), but no correlation was found
among these abnormalities and the duration and severity of the
disease (Ghezzi et al., 1989).
In addition, in ALS patients the P1 component was also
found to be absent, and the P300 component was delayed
and attenuated (Münte et al., 1998). In a study of six ALS
patients, only one patient with a 9-month disease evolution
had abnormal P100 bilateral extension VEPs and a significant
interocular difference of P100. In addition, none of the patients
presented alterations in their electroretinogram (González Díaz
et al., 2004). Subsequently, electrophysiological studies of ALS
patients showed new evidence of cortical participation involving
visual areas, with alterations in the early sensory components of
VEPs (Münte et al., 1998).
Contrast Sensitivity
While one study revealed impaired contrast sensitivity during
an eye examination in two ALS patients with C9orf72 mutation
(Fawzi et al., 2014), another study concluded that this function
is not affected in ALS patients (Volpe et al., 2015; Table 2
and Figure 2).
Visual Acuity
Visual acuity in ALS patients is controversial. While a study found
a lower visual acuity in ALS patients in both high-contrast and
low-contrast (2.5% and 1.5%) visual acuity with Sloan charts
(Moss et al., 2012), in others, the visual acuity exam revealed no
differences in monocular high-contrast visual acuity (Volpe et al.,
2015; Moss et al., 2016; Rojas et al., 2019) or low-contrast visual
acuity (Moss et al., 2016).
Visual Field
Only two studies describe VF in early ALS spinal onset patients.
With a decrease of mean sensitivity and an increase of the square
of loss variance (Liu et al., 2018), ALS patients presented a worse
reliability index (fixation losses, false positives, and negatives) due
to motor difficulties. For this reason, the authors suggested that
VF is not a suitable test to assess ALS patients (Rojas et al., 2019;
Table 2 and Figure 2).
Retinal Abnormalities in Amyotrophic
Lateral Sclerosis
Retinal tissue can be analyzed using histological techniques on
postmortem tissues or using the OCT technique mentioned
above. This technique is an optical analog of ultrasonic imaging
using low-coherence interferometry to produce cross-sectional
images of the retina and allows in vivo observation of retinal
tissue alterations (Bhende et al., 2018).
Retinal Histopathological Studies in Amyotrophic
Lateral Sclerosis Patients and Amyotrophic Lateral
Sclerosis Experimental Models of Mammals
Few studies have focused on the histopathology of retinal tissue
in both ALS patients and animal models of mammals with
this condition. Histopathological studies in ALS patients
demonstrated intraretinal protein inclusions. The first
histopathological analysis of the retinas of patients with
ALS was performed in 2014 on a patient with the C9orf72
mutation. In this study, the authors found p62-positive and
pTDP43-negative intracytoplasmic perinuclear inclusions in
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TABLE 2 | Psychophysics visual test studies in ALS patients.
Study and year of
publication
Alterations in visual functions in ALS
VEP ERG VA VF CS
Matheson et al., 1986 Abnormal latencies
between eyes
– – – –
Ghezzi et al., 1989 WNL – – – –
Münte et al., 1998 P300 delayed and
attenuated
P1 absent – – –
González Díaz et al., 2004 P100 latency prolongation WNL – – –
Fawzi et al., 2014 – – – – ↓CS
Volpe et al., 2015 – – No changes high contrast VA – No changes
Moss et al., 2016 – – ↓High contrast and low contrast VA – –
Liu et al., 2018 – – – MS↓ and ↑sLV –
Rojas et al., 2019 – – No changes high contrast VA ↓ reliability index (↑fixation losses,
↑false positives and negatives)
–
ALS, amyotrophic lateral sclerosis; VEP, visual evoked potentials; ERG, electroretinogram; VA, visual acuity; VF, visual field; CS, contrast sensitivity; WNL, within normal
limits; MS, mean sensibility; sLV, square of loss variance.
the inner nuclear layer (INL). These deposits were similar to
those observed in the dentate gyrus of ALS patients with the
C9orf72 mutation. The p62-positive staining was colocalized
for both the poly-(GA)n dipeptide repeat and ubiquitin in the
retina, which is similar to the perinuclear inclusions located
in the brains of patients with this mutation. The p62-positive
inclusions found were likely located in specific cone bipolar
cells and within the amacrine and horizontal cells, as they were
also marked with GLT-1 and recoverin. The authors suggested
that these deposits may be related to the affectation of contrast
sensitivity (Fawzi et al., 2014). In addition, in other ALS patients
with C9orf72 mutations, specific p62 inclusions were observed in
the retinal ganglion cell layer (GCL) in a far smaller proportion
than in INL (94.9% in INL vs. 5.1% in GCL). Numerous positive
ubiquitin2 + aggregates were also observed in a mutant UBQLN2
transgenic mice experimental model, mainly in the INL, with
fewer in the outer plexiform layer (OPL) and some in the GCL
(Volpe et al., 2015). The accumulation of ubiquitin2 aggregates
in the layers of the retina with more synapses is related to the
accumulation of these aggregates in the dendritic spines of the
hippocampus. The location of the aggregates at the synapses,
and their spines, may be associated with the dementia observed
in this experimental model of ALS. In addition, few ubiquitin2
positive aggregates were detected in the subretinal space of
the retinal pigment epithelium, which sometimes elevated
these levels in the same way as druses (Volpe et al., 2015).
Furthermore, lipofuscin deposits sometimes related to subretinal
drusen-like aggregates were found in progranulin-deficient FTD
patients (Ward et al., 2017). Retinal thinning in these patients
was detected by OCT before symptoms, suggesting that the eye is
affected in progranulin-deficient FTD disease (Ward et al., 2014).
As noted previously, microglial and astroglial cell activation
occurs in ALS. However, to our knowledge, there are only two
works that analyzed the glial cells of the retina in relation to
ALS. hSOD1 + vacuoles located in the dendrites of excitatory
retinal neurons were observed in a mouse model of ALS SOD1
(SOD1G93A), mainly in the inner plexiform layer (IPL) and
rarely in the GCL and INL. However, there were no signs
of activation of either the astroglia or the microglia of the
retina compared with those of wild-type mice (Ringer et al.,
2017). In contrast, microglial activation was demonstrated in a
mouse model of ALS [devoid of ran-binding protein2 (Ranbp2)].
Ranbp2 is a protein involved in nucleo-cytoplasmic transport
whose regulation is impaired in both SALS and FALS (Ferreira,
2019). In ALS mice without this protein (with respect to wild-
type controls), there was an increase in the number of CD45 +,
CD11b +, and F4/80 + microglial cells surrounding the RGCs, in
addition to a notable increase in amoeboid forms. An increase
of metalloproteinase 28, which is an immune regulator, was also
observed in the RGCs, suggesting that Ranbp2 may be involved in
the signaling between the microglia and the RGCs in the immune
response of ALS disease (Cho et al., 2019; Figure 2).
Optical Coherence Tomography
Although the first study performed in 75 ALS patients with Cirrus
OCT showed no changes in the peripapillary and macular areas
(Roth et al., 2013), further studies have shown that there are
changes in the retina of ALS patients (Ringelstein et al., 2014;
Volpe et al., 2015; Hübers et al., 2016; Simonett et al., 2016;
Mukherjee et al., 2017; Abdelhak et al., 2018; Liu et al., 2018;
Rohani et al., 2018; Rojas et al., 2019; Table 3).
In the retina of ALS patients, high-resolution SD-OCT
revealed reduction in the mean total macular thickness,
in the peripapillary retinal nerve fiber layer (pRNFL), the
INL (Ringelstein et al., 2014; Hübers et al., 2016), and the
outer nuclear layer (ONL) (Abdelhak et al., 2018), suggesting
neurodegeneration of the retina in ALS patients.
Volpe et al. studied whether clinical and histopathological
findings were present in the eyes of ALS patients and explored
their correlation with an animal model (ALS/dementia transgenic
mice with dysfunctional ubiquilin2, UBQLN2P497H) (Volpe
et al., 2015). Using SD-OCT, the authors observed that (i)
in ALS patients compared with the controls, there was a
decrease in total macular volume; (ii) 37.5% of ALS patients
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showed an average pRNFL below the first percentile, and
temporal and papillomacular bundle were more affected; and
(iii) in ALS patients, the total macular thickness and pRNFL
thickness correlated inversely with the time of evolution of ALS
(Volpe et al., 2015).
Recently, in a study performed in early ALS patients with
spinal onset and without ocular diseases, a significant macular
thickness increase was found in the temporal and inferior
areas of the inner macular ring in comparison with that in
a healthy control, suggesting that this retinal thickening in
early ALS patients could be due a microglial activation in the
neuroinflammatory process (Ringelstein et al., 2014; Rojas et al.,
2019). In contrast, in another study in ALS patients, only the
macular retinal nerve fiber layer (mRNFL) showed a significant
thickness decrease by OCT, which correlated positively with
pulmonary function tests (Simonett et al., 2016). However,
neither total macular thickness nor macular thickness showed
changes (Simonett et al., 2016).
Only one study exists that detected a thinning in the ONL
(Abdelhak et al., 2018), suggesting a possible impact on the
photoreceptors and linking this finding with this subclinical
visual acuity impairment (Moss et al., 2012; Abdelhak et al.,
2018). Using SD-OCT, this work analyzed the retinal vessels,
finding that in ALS patients compared with the control, the outer
wall thickness of the retinal vessels was higher than in the control
group (Abdelhak et al., 2018). Similar microvascular alterations
in the brain and spinal cord of ALS model mice were found to
precede the degeneration of motor neurons (Zhong et al., 2008).
In ALS patients, an analysis of the relationship of clinical
features and retinal changes using SD-OCT and diffusion tensor
imaging (DTI) found no significant correlation between clinical
features and retinal thickness; however, there was a direct
correlation between retinal thickness and fractional anisotropy
of the corticospinal tract (Hübers et al., 2016). On the basis of
these observations, it was suggested that retinal changes could be
related to damage of white matter in the corticospinal tract and
may be a possible biomarker in ALS (Hübers et al., 2016).
Although several papers have demonstrated the pRNFL
decrease in ALS patients without ocular pathology (Mukherjee
et al., 2017; Rohani et al., 2018; Rojas et al., 2019), there is
controversy about its correlation with ALSFRS-R values. While
one study did not demonstrate a correlation between RNFL
thickness and the ALSFRS-R score and their progression rates
(Mukherjee et al., 2017), other authors found a correlation
with some OCT parameters (Abdelhak et al., 2018; Liu et al.,
2018; Rohani et al., 2018; Rojas et al., 2019; Salobrar-García
et al., 2019). In a study of the pRNFL thickness in four
quadrants, the average pRNFL thickness showed a significant
positive correlation with the ALSFRS-R score (Rohani et al.,
2018), and the pRNFL thickness in the inferior sector was
negative (Rojas et al., 2019). When the analysis was more
detailed, dividing the papilla into 12 hourly sectors, sectors
H5 and H6 had a positive direct significant correlation, and
H8 had an inverse significant correlation of pRNFL with the
ALSFRS-R values (Rojas et al., 2019). In addition, the entire
retinal thickness correlated negatively with the ALSFRS-R score
(Abdelhak et al., 2018).
Follow-up OCT studies of ALS patients are very rare. In
the only one performed of early ALS patients with spinal
onset (basal patients) who were examined 6 months after
the basal scan (follow-up patients), the SD-OCT follow-
up analysis of ALS patients showed a significant macular
thickness decrease in the inferior areas of the inner and outer
macular ring and a significant pRNFL thickness decrease in the
superior and inferior quadrants, compared with the baseline
(Rojas et al., 2019).
Asymmetry is a typical hallmark of ALS, as mentioned
above. In the left eye (LE) of ALS patients, after adjustment
for multiplicity, there was a significant decrease in pRNFL
thickness in the nasal quadrant compared with the corresponding
quadrant thickness in the right eye (RE) (Rohani et al., 2018).
In the follow-up study mentioned above (Rojas et al., 2019),
there were significant interocular asymmetries in some areas
between the LE, which were always thinner, and the RE were
observed. In the baseline ALS group, in the LE, the inferior-
nasal quadrant of the macular ganglion cell complex (GCC), and
the H7 and H9 hourly-sectors of the pRNFL were significantly
thinner than those in the RE, while in the follow-up ALS
group, both the supero-nasal quadrant of macular GCC and
the temporal quadrant, and the H8 and H9 hourly sectors of
the pRNFL, were significantly thinner in the LE than those
in the RE. Therefore, the asymmetric participation of the
CNS in this disease is not exclusive to the motor system
(Rohani et al., 2018).
Thinning of the inner retina was also observed by SD-OCT in
other neurodegenerative diseases, including Alzheimer’s disease
and Parkinson’s disease, in which both RNFL and GCL thinning
were detected (Moreno-Ramos et al., 2013; Coppola et al.,
2015; Salobrar-García et al., 2015b; Garcia-Martin et al., 2016).
However, in FTD, OCT identified ONL thinning, specifically
in the ellipsoid zone, and this thinning of the outer retina
correlated with cognitive changes (Kim et al., 2017). Moreover,
the relationship between ONL thinning and FTD was especially
apparent in the subgroup of patients considered to have
“likely tauopathy” based on their symptoms or their genetics
(Kim et al., 2017).
The differences observed in retinal thickness measurements
using OCT may be due to the following: (i) the different
disease stages of ALS patients included in the studies; (ii) the
heterogeneous nature of this pathology (Hübers et al., 2016); and
(iii) the small number of participants in these studies, since most
ALS patients do not manifest visual problems.
Many authors observed changes in retinal thickness, as shown
in this section. Therefore, retinal changes constitute a biomarker
of neurodegeneration and progression of ALS disease (Hübers
et al., 2016; Rohani et al., 2018), and OCT analysis is a useful tool
for the study of this pathology (Rojas et al., 2019).
CONCLUSION
In view of the above, changes in visual function are moderate in
ALS. The main changes occur at the oculomotor level, but with
no great affect. Functional tests such as VA, contrast sensitivity,
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VF, and VEPs show mild alterations in ALS. However, the low
rate of functional impairment does not mean that there are
no structural changes in the visual pathway in ALS patients.
New techniques such as OCT have made it possible to detect
structural changes in the retina (due to retrograde or anterograde
involvement), but which ultimately reflect changes in the
visual pathway. These changes monitored with OCT could
help to follow up this pathology. However, these studies are
recent and are not homogeneous due to differences in the
patients’ degree of disease, time of evolution, age group, or
ALS scores. In addition, differences in the OCT technology
make it difficult to compare between the different studies.
Thus, it is necessary to perform more studies to analyze the
retinal changes that occur in ALS disease. In addition, there
are also many unanswered questions, including when and
where the changes in the retina first occur, which subgroups
of patients exhibit retinal phenotypes, and whether these
phenotypes change over time. Longer studies are needed to
determine whether retinal thickness might be a useful way to
measure disease progression and whether patients with different
genetic mutations that cause ALS experience more severe
retinal involvement.
We conclude that, in addition to CNS disorders, there
are also peripheral neurological diseases that can affect the
retina. We have shown that the retina has great sensitivity
as a biomarker for susceptibility/risk in MND, despite the
fact that the retinal changes do not produce clinical visual
symptoms. Therefore, the use of OCT in ALS patients could
be a recommended test within the diagnostic techniques
of this pathology.
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